Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-15T01:57:22.907Z Has data issue: false hasContentIssue false
  • English
  • Français

Lithium and Suicide Risk in Bipolar Disorder

Published online by Cambridge University Press:  07 November 2014

Leonardo Tondo ,
Ross J. Baldessarini  and
John Hennen
Get access Rights & Permissions [Opens in a new window]

Abstract

Can timely diagnosis and treatment of depression reduce the risk of suicide? Studies of treatment effects on mortality in major mood disorders remain rare and are widely considered difficult to carry out ethically. Despite close associations of suicide with major affective disorders and related comorbidity, the available evidence provides little support for sustained reductions of suicide risk by most mood-altering treatments, including antidepressants. Studies designed to evaluate clinical benefits of mood-stabilizing treatments in bipolar disorders, however, provide comparisons of suicidal rates with and without treatment or under different treatment conditions. This emerging body of research provides consistent evidence of reduced rates of suicides and attempts during long-term treatment with lithium. This effect may not generalize to proposed alternatives, particularly carbamazepine. Our recent international collaborative studies found compelling evidence for prolonged reduction of suicidal risks during treatment with lithium, as well as sharp increases soon after its discontinuation, all in close association with depressive recurrences. Depression was markedly reduced, and suicide attempts were less frequent, when lithium was discontinued gradually. These findings indicate that studies of the effects of long-term treatment on suicide risk are feasible and that more timely diagnosis and treatment for all forms of major depression, but particularly for bipolar depression, should further reduce suicide risk.

Type
Academic Supplement
Information
CNS Spectrums , Volume 5 , supplement S1: Suicide: Risk Assessment and Pharmacologic Intervention , February 2000 , pp. 6 - 11
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Angst, J, Stassen, HH, Gross, G, Huber, G, Stone, MH. Suicide in affective and schizoaffective disorders. In: Marneros, A, Tsuang, MT, eds. Affective and Schizoaffective Disorders. Berlin, Germany: Springer-Verlag; 1990:168–185.CrossRefGoogle Scholar
2.Goodwin, FK, Jamison, KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.Google Scholar
3.Coppen, A. Depression as a lethal disease: prevention strategies. J Clin Psychiatry. 1994;55(suppl 4):37–45.Google ScholarPubMed
4.Sharma, R, Markar, HR. Mortality in affective disorders. J Affect Disord. 1994;31:91–96.CrossRefGoogle Scholar
5.Ahrens, B, Müller-Oerlinghausen, B, Schou, M, et al.Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disord. 1995;33:33–67.CrossRefGoogle ScholarPubMed
6.Tondo, L, Jamison, KR, Baldessarini, RJ. Antisuicide effects of lithium. Ann NY Acad Sci. 1997;836:836–339.Google ScholarPubMed
7.Angst, J, Sellaro, R, Angst, F. Long-term outcome and mortality of treated vs untreated bipolar and depressed patients: a preliminary report. Int J Psychiatr Clin Pract. 1998;2:2–115.CrossRefGoogle Scholar
8.Baldessarini, RJ, Tondo, L. Effects of lithium treatment in bipolar disorders and post-treatment-discontinuation recurrence risk. Clin Drug Investigation. 1998;15:15–337.CrossRefGoogle ScholarPubMed
9.Tondo, L, Baldessarini, RJ, Floris, G, Silvetti, F, Hennen, J, Tohen, M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry. 1998;59:59–405.CrossRefGoogle ScholarPubMed
10.Angst, J, Angst, F, Stassen, HS. Suicide risk in patients with major depressive disorder. J Clin Psychiatry. 1999;60(suppl 2):57–62.Google ScholarPubMed
11.Baldessarini, RJ, Jamison, KR. Effects of medical interventions on suicidal behavior: summary and conclusions. J Clin Psychiatry. 1999;60(suppl 2):117–122.Google ScholarPubMed
12.Jamison, KR, Baldessarini, RJ. Effects of medical interventions on suicidal behavior: introduction. J Clin Psychiatry. 1999;60(suppl 2):4–6.Google ScholarPubMed
13.Guze, SB, Robins, E. Suicide and primary affective disorders. Br J Psychiatry. 1970;117:117–437.CrossRefGoogle ScholarPubMed
14.Roy, A. Suicide in recurrent affective disorder patients. Can J Psychiatry. 1984;29:29–319.CrossRefGoogle ScholarPubMed
15.Taube, CA, Barrett, SA, eds. Mental Health: United States. NIMH Publication AOM-85-1378. Washington, DC: US Government Printing Office; 1985.Google Scholar
16.Roy, A. Suicide. In: Kaplan, HI, Sadock, BJ, eds. Comprehensive Textbook of Psychiatry. Vol 2. 9th ed. Baltimore, Md: Williams & Wilkins; 1989:1414–1427.Google Scholar
17.Tondo, L, Baldessarini, RJ, Hennen, J, et al.Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry. 1999;60(suppl 2):63–69.Google ScholarPubMed
18.Faedda, GL, Baldessarini, RJ, Suppes, T, Tondo, L, Becker, I, Lipschitz, D. Pediatric-onset bipolar disorder a neglected clinical and public health problem. Harvard Rev Psychiatry. 1995;3:3–171.CrossRefGoogle ScholarPubMed
19.Committee on Adolescence. Adolescent Suicide. Washington, DC: American Psychiatric Press; 1996:39–55.Google Scholar
20.Baldessarini, RJ, Tondo, LAntisuicidal effect of lithium treatment in major mood disorders. In: Jacobs, D, ed. Harvard Medical School Guide to Assessment and Intervention in Suicide. San Francisco, Calif: Jossey-Bass; 1998:355–371.Google Scholar
21.Baldessarini, RJ, Tondo, L, Hennen, J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry. 1999;60(suppl 2):77–84.Google ScholarPubMed
22.Kessler, RC, McGonigle, KA, Zhao, S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:51–8.CrossRefGoogle ScholarPubMed
23.Tondo, L, Baldessarini, RJ, Hennen, J, Floris, G. Lithium maintenance treatment: depression and mania in bipolar I and II disorders. Am J Psychiatry. 1998;155:155–638.CrossRefGoogle Scholar
24.Keller, MB, Lavori, PW, Klerman, GL, et al.Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry. 1986;43:43–458.CrossRefGoogle ScholarPubMed
25.McCombs, JS, Nichol, MB, Stimmel, GL, Sclar, DA, Beasley, CM Jr, Gross, LS. Cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51(suppl 6):60–69.Google Scholar
26.Isacsson, G, Boethius, G, Bergman, U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand. 1992;85:85–444.CrossRefGoogle ScholarPubMed
27.Baldessarini, RJ, Tondo, L, Suppes, T, Faedda, GL, Tohen, M. Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Shulman, KI, Tohen, M, Kutcher, S, eds. Bipolar Disorder Through the Life-Cycle. New York, NY: Wiley & Sons; 1996:299–338.Google Scholar
28.Suominen, KH, Isometsä, E, Hendriksson, MM, Ostamo, Al, Lönnqvist, JK. Inadequate treatment for major depression both before and after attempted suicide. Am J Psychiatry. 1998;155:155–1778.CrossRefGoogle ScholarPubMed
29.Gunell, D, Frankel, S. Prevention of suicide: aspirations and evidence. Br Med J. 1994;308:308–1227.Google Scholar
30.Wyatt, RJ, Henter, I. An economic evaluation of manic-depressive illness. Soc Psychiatry Psychiatr Epidemiol. 1995;30:30–213.CrossRefGoogle ScholarPubMed
31.Müller-Oerlinghausen, B, Berghöfer, A. Antidepressants and suicidal risk. J Clin Psychiatry. 1999;60(suppl 2):94–99.Google ScholarPubMed
32.Avery, D, Winokur, G. The efficacy of electroconvulsive therapy and antidepressants in depression. Biol Psychiatry. 1977;12:12–507.Google ScholarPubMed
33.Teicher, MH, Glod, CA, Cole, JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety. 1993;3:3–186.Google Scholar
34.Freemantle, N, House, A, Song, F, Mason, JM, Sheldon, TA. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. Br Med J. 1994;309:309–249.CrossRefGoogle ScholarPubMed
35.Verkes, RJ, Van der Mast, RC, Hengeveld, MW, Tuyl, JP, Zwinderman, AH, Van Kempen, GMJ. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998;155:155–543.CrossRefGoogle Scholar
36.Leon, AC, Keller, MB, Warshaw, MG, et al.Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry. 1999;156:156–195.CrossRefGoogle ScholarPubMed
37.Montgomery, SA, Dunner, DL, Dunbar, GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol. 1995;5:5–5.CrossRefGoogle ScholarPubMed
38.Baldessarini, RJ. Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Hardman, JG, Limbird, LE, Molinoff, PB, Ruddon, RW, Gilman, AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Press; 1996:431–459.Google Scholar
39.Ohberg, A, Lonqvist, J, Sarna, S, Vuori, E, Penttila, A. Trends and availability of suicide methods in Finland: proposals for restrictive measures. Br J Psychiatry. 1995;166:166–35.CrossRefGoogle ScholarPubMed
40.Mosciki, EK. Epidemiology of suicide. In: Jacobs, D, ed. Harvard Medical School Guide to Assessment and Intervention in Suicide. San Francisco, Calif: Jossey-Bass; 1998:40–51.Google Scholar
41.Zornberg, GL, Pope, HG Jr. Treatment of depression in bipolar disorder new directions for research. J Clin Psychopharmacol. 1993;13:13–397.CrossRefGoogle ScholarPubMed
42.Faedda, GL, Tondo, L, Baldessarini, RJ, Suppes, T, Tohen, M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar mood disorders. Arch Gen Psychiatry. 1993;50:50–448.CrossRefGoogle Scholar
43.Suppes, T, Baldessarini, RJ, Faedda, GL, Tondo, L, Tohen, M. Discontinuing maintenance treatment in bipolar manic-depression: risks and implications. Harvard Rev Psychiatry. 1993;1:1–131.CrossRefGoogle ScholarPubMed
44.Baldessarini, RJ, Suppes, T, Tondo, L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Therapeutics. 1996;3:3–492.CrossRefGoogle ScholarPubMed
45.Baldessarini, RJ, Tondo, L, Faedda, GL, Floris, G, Suppes, T, Rudas, T. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. J Clin Psychiatry. 1996;57:57–441.CrossRefGoogle ScholarPubMed
46.Baldessarini, RJ, Tondo, L, Viguera, A. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disorders. In press.Google Scholar
47.Viguera, AC, Baldessarini, RJ, Friedberg, J. Risks of interrupting continuation or maintenance treatment with antidepressants in major depressive disorders. Harvard Rev Psychiatry. 1998;5:5–293.Google Scholar
48.Viguera, AC, Baldessarini, RJ, Hegarty, JM, Van Kammen, D, Tohen, M. Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry. 1997;54:54–49.Google Scholar
49.Modestin, J, Schwartzenbach, F. Effect of psychopharmacotherapy on suicide risk in discharged psychiatric inpatients. Acta Psychiatr Scand. 1992;85:85–173.CrossRefGoogle ScholarPubMed
50.Müller-Oerlinghausen, B, Müser-Causemann, B, Volk, J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord. 1992;25:25–261.CrossRefGoogle Scholar
51.Crundwell, JK. Lithium and its potential benefit in reducing increased mortality rates due to suicide. Lithium. 1994;5:5–193.Google Scholar
52.Felber, W, Kyber, A. Suizide und parasuizide während und ausserhalb einer lithium prophylaxe. In: Müller-Oerlinghausen, B, Berghöfer, A, eds. Ziele und Ergebnisse der Medikamentösen Prophylaxe Affektiver Psychosen. Stuttgart, Germany: G Thieme Verlag; 1994:53–59.Google Scholar
53.Lenz, G, Ahrens, B, Denk, E, et al.Mortalität nach Ausschneiden aus der Lithiumambulanz [Increased mortality after drop-out from lithium clinic]. In: Müller-Oerlinghausen, B, Berghöfer, A, eds. Ziele und Ergebnisse der Medicamentösen Prophylaxe Affecktiver Psychosen. Stuttgart, Germany: G Theme Verlag; 1994:49–52.Google Scholar
54.Nilsson, A. Mortality in recurrent mood disorders during periods on and off lithium: a complete population study in 362 patients. Pharmacopsychiatry. 1995;28:28–8.CrossRefGoogle ScholarPubMed
55.Bocchetta, A, Ardau, R, Burrai, C, Chillotti, C, Quesada, G, Del Zompo, M. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. J Clin Psychopharmacol. 1998;18:18–384.CrossRefGoogle Scholar
56.Nilsson, A. Lithium therapy and suicidal risk. J Clin Psychiatry. 1999;60(suppl 2):85–88.Google Scholar
57.Wickham, EA, Reed, FV. Lithium for the control of aggressive and self-mutilating behavior. Int Clin Psychopharmacol. 1977;2:2–181.Google Scholar
58.Cappiello, A, Sernyak, MJ, Malison, RT, McDougle, CJ, Heninger, GR, Price, LH. Effects of acute tryptophan depletion in lithium-remitted manic patients: a pilot study. Biol Psychiatry. 1997;42:42–1076.CrossRefGoogle ScholarPubMed
59.Mann, JJ, Oquendo, M, Underwood, MD, Arango, V. The neurobiology of suicide risk: a review for the clinician. J Clin Psychiatry. 1999;60(suppl 2):7–11.Google Scholar
60.Thies-Flechtner, K, Müller-Oerlinghausen, B, Seibert, W, Walther, A, Greil, W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Pharmacopsychiatry. 1996;29:29–103.CrossRefGoogle ScholarPubMed
61.Greil, W, Ludwig-Mayerhofer, W, Erazo, N, et al.Lithium vs carbamazepine in the maintenance treatment of bipolar disorders: a randomized study. J Affect Disord. 1997;43:43–151.CrossRefGoogle Scholar
62.Meltzer, HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry. 1998; 59 (suppl 3):95201Google ScholarPubMed
63.Banov, MD, Zarate, CA Jr, Tohen, M, et al.Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994;55:55–295.Google ScholarPubMed
64.Zarate, CA, Tohen, M, Baldessarini, RJ. Clozapine therapy in severe mood disorders. J Clin Psychiatry. 1995;56:56–411.Google ScholarPubMed
65.Baldessarini, RJ, Frankenburg, FR. Clozapine: a novel antipsychotic agent. N Engl J Med. 1991;24:24–746.Google Scholar
66.Meltzer, HY, Nash, JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev. 1991;43:43–587.Google ScholarPubMed